12-Ethyl-6-(15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-yl)-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6-trien-3-ol

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - Eburnan型生物碱
• 英文名称: 12-Ethyl-6-(15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-yl)-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6-trien-3-ol
• 英文别名: 12-ethyl-6-(15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-yl)-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6-trien-3-ol
• 化学式: C₃₈H₄₈N₄O
• 分子量: 576.8
• InChiKey: HHCOPHVLECRPRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  43
• 可旋转键数：
  3
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• MELONINE BISINDOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHOD AND USE THEREOF
  申请人：Luo Xiaodong

  公开号：US20120283284A1

  公开（公告）日：2012-11-08

  The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers.
• US9163035B2
  申请人：——

  公开号：US9163035B2

  公开（公告）日：2015-10-20